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The incidence of tongue cancer is increasing worldwide, and its aggressiveness remains high regardless of treatment. Genetic
changes and the expression of abnormal proteins have been frequently reported in the case of head and neck cancers, but the
little information that has been published concerning tongue tumours is often contradictory. This review will concentrate on the
immunohistochemical expression of biomolecular markers and their relationships with clinical behaviour and prognosis. Most
of these proteins are associated with nodal stage, tumour progression and metastases, but there is still controversy concerning
their impact on disease-free and overall survival, and treatment response. More extensive clinical studies are needed to identify
the patterns of molecular alterations and the most reliable predictors in order to develop tailored anti-tumour strategies based
on the targeting of hypoxia markers, vascular and lymphangiogenic factors, epidermal growth factor receptors, intracytoplasmatic
signalling and apoptosis.
Copyright © 2009 Daris Ferrari et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Oral cancer is the most frequent cancer aﬀecting the
cervicofacial district, causing about 8000 deaths every year
in the United States [1, 2], and cancer of the tongue accounts
for approximately 30% of all oral cancers. The most frequent
histological type is squamous cell carcinoma (SCC) which
mainly aﬀects men in the sixth decade of life [3–6]. The
incidence of tongue cancer increased from 1973 to 2001 at
thesamerhythmastonsilcancer,andabout10,000newcases
were recorded in the United States in 2007 [7]. According to
the Scandinavian registries, the trend towards an increasing
incidence only excludes women 65–79 years old [8].
Unlike other studies, survival analyses have demon-
strated that survival rates are better among young adults
than older patients [9–11], with a 5-year crude survival rate
of 65% (95% CI 59–71%) against 45% (95% CI 43–48%)
in subjects aged 40–64 years and 33% (95% CI 31–35%)
in those aged 65–79 years. Base of the tongue cancer has a
poorer prognosis than mobile tongue cancer; according to
US National Cancer Database ﬁndings, the 5- and 10-year
disease-speciﬁc survival (DSS) rates for base of the tongue
tumours are, respectively, 40.3% and 29.4%, and overall
survival (OS) rates are, respectively, 27.8% and 12.2%. An
older age (>65 years), low economic income, and advanced
stage are independently associated with lower DSS, which is
64.7% for stage I and 30.0% for stage IV [12].
Smoking and alcohol consumption are recognised risk
factors for tongue cancer, but are frequently not involved in
the case of younger patients [13, 14]. Head and neck cancer
(HNC)isheraldedbysomechangesingeneticandepigenetic
patterns, with gene inactivation or ampliﬁcation being the
main alterations that can lead to derangements in the molec-
ular pathways involved in regulating cell behaviour [15–23].
Al-Moustafaet al. [24] found that genes encoding for growth
factors and cell structure were overexpressed in 0.7% of
their cases, and those involved in cell motility and apoptosis
were underexpressed in 1%: more speciﬁcally, at protein
level, Wnt-5a, ﬁbronectin and N-cadherin were upregulated,
whereas E-cadherin, claudin-7, the catenins, and connexin
31.1 were downregulated. However, the speciﬁc relationships
between genes and proteins, the ﬁnal alteration that may
imprint the neoplastic clone and its development, have not
yet been ascertained.
Ongoing biological research is attempting to establish
whether these proteins can be considered biomarkers that
could guide therapeutic choices. SCC of the tongue is
characterised by an unpredictable course as some patients
with early lesions may develop local recurrence and regional2 Journal of Oncology
metastases despite adequate surgery, and so the identiﬁ-
cation of prognostic markers would enable clinicians to
target patients who may beneﬁt from a speciﬁcally tailored
treatment strategy.
This review will concentrate on the most recent advances
in the rapidly evolving ﬁeld of biomarker research in this
tumour type.
2. ViralInfections
Two viruses are commonly associated with HNC. The
integration of Epstein-Barr virus (EBV) into mucosal cells
is the most important pathogenetic factor in the develop-
ment of nasopharyngeal carcinoma, which is endemic in
geographical areas such as the Middle East and South-East
Asia, the Arctic area, and Northern Africa [25–30]. EBV is
transmittedthroughsaliva,butitscellsourceiscontroversial,
although putative reservoirs include the oral epithelium and
salivary glands. Frangou et al. [31] observed EBV replication
in 1.3% of tongue mucosal samples, but no latent infection
was found, and EBV infection was not detected in the tongue
carcinomas. It is, therefore, reasonable to argue that EBV
replication occurs infrequently in tongue epithelial cells, and
that EBV is probably not involved in the pathogenesis of
tongue cancer.
Oropharyngeal cancer is closely associated with human
papilloma virus (HPV), whose growing incidence in young
adults accounts for a proportional increase in the incidence
of tonsil cancer. Subtypes 16 and 18 are commonly involved
in the pathogenesis of oropharyngeal carcinoma [32], and
are suspected of increasing the risk of tongue cancer by 3–
5t i m e s[ 33–35]. The prevalence of HPV in tongue cancer
varies considerably but, when it is present, the median copy
numbers of E6 DNA in nontonsillar specimens is approx-
imately 80,000 times lower than in tonsillar specimens
[36]. Kantola et al. [37] found that none of 105 mobile
tongue cancer patients harboured HPV, and two studies have
reported HPV frequencies in oral tongue cancer of 2.3% and
1.96%, thus conﬁrming its small etiopathogenetic role, at
least in the mobile portion of the tongue [38, 39]. Liang et
al. [39] reported a higher incidence of HPV in base of the
tongue cancer (51.5%), and Dahlgren et al. [38] stated that
mobile and base of the tongue SCC are diﬀerent diseases,
with HPV being present in 40% of the patients aﬀected by
the latter and, as has been observed in the case of tonsillar
cancer, the presence of HPV in base of the tongue cancer
positively inﬂuenced survival (P = .0159). Interestingly, the
HPV-positive base of the tongue cancer patients still had an
advantage over those who were HPV-negative in terms of
5-year DSS (P = .0362), whereas tumour stage at the time
of diagnosis no longer had an impact (P = .0863) [38].
The presence of HPV is, therefore, clearly associated with
a better prognosis, and outweighs the predictive value of
disease stage.
3.Hypoxia:Follow-Up (a)
Deranged vascular architecture and necrotic changes within
neoplastic tissue are responsible for tumour hypoxia, which
is associated with a poor outcome in HNC patients [40, 41].
Poorly oxygenated tumours have a poor prognosis as they
may be resistant to radio- and chemotherapy, and favour
malignant progression [42–45]. Tumour cells harbouring
genetic alterations survive longer than normal cells in
a hypoxic environment and are more likely to transmit
genomic instability as a consequence of selective pressure,
after which the neoplastic clone can easily grow, increase
angiogenesis and motility, and ﬁnally spread through the
lymphatic system or blood vessels [45–48].
It is thought that hypoxia upregulates some highly
expressed proteins that are easily recognised immunohisto-
chemically and may act as endogenous biomarkers in HNC
[45]. Hypoxia-inducible factor 1a (HIF-1α) is a partner in a
dimer that acts as a transcription factor by binding a speciﬁc
DNA sequence and activating gene transcription. Under
hypoxic conditions, HIF-1α levels increase and activate
genes coding for growth and angiogenesis factors, as well
as glycolytic enzymes. It has been demonstrated that such
genes, particularly, carbonic anhydrase IX (CA-9), vascu-
lar endothelial growth factor (VEGF), and erythropoietin
(EPO),arehighlyexpressedinHNC[49,50]buttransferring
immunohistochemical results to the clinical setting in order
to identify their real prognostic value and impact on clinical
practice is diﬃcult.
R o he ta l .[ 51], retrospectively, studied T2 tongue cancer
using monoclonal antibodies against HIF-1α,H I F - 2 α,C A -
9, the glucose transporter (GLUT-1) and EPO receptors
(EPORs), and found that only GLUT-1 was related to nodal
stage and could, therefore, be used as a potential predictor
of nodal metastates. Univariate analysis showed that HIF-
1α and EPOR expression signiﬁcantly correlated with DSS
(P<. 05), but not with other clinicopathological variables
such as tumour thickness, nodal involvement, and resection
margin status, and multivariate analysis showed that only
EPOR expression remained a signiﬁcant predictor of DSS
(P = .030). However, the small number of patients and the
fact that they all had T2 tongue cancer makes it diﬃcult to
draw any deﬁnite conclusions.
The role of exogenous hypoxia markers is beyond
the scope of this review, but it is worth mentioning the
role of pimonidazole, a marker of exogenous hypoxia in
human SCC of the cervix and head and neck [52–54].
The pimonidazole binding assay is a direct indicator of
tumour hypoxia, which has been proved to be signiﬁcantly
associatedwithlocoregionalcontrolanddisease-freesurvival
(DFS) [55]. Patients with hypoxic tumors show a worse
initial response to treatment and have more locoregional




Vascular endothelial growth factors (VEGFs) are a family of
proteinswithspeciﬁcangiogenicpropertiesthatincreaseves-
sel permeability, and endothelial cell growth, proliferation,Journal of Oncology 3
migration, and diﬀerentiation [56, 57]. VEGF-A/vascular
permeability factor and VEGF-C have been recently recog-
nised as lymphangiogenic/angiogenic factors that induce
lymph and blood vessel hyperplasia and facilitate tumour
progressionandmetastases[58,59].VEGF-Aconsistsoffour
isoforms with a diﬀerent molecular mass (121, 165, 189,
and 206 amino acids) and diﬀerent biological activity [60].
VEGF-C is structurally very similar to VEGF-D, and both
of these and their major receptors (VEGFR-2 and VEGFR-
3) are expressed in many cancer cells and may regulate
lymphangiogenesis by facilitating the signalling network
between endothelial and cancer cells [61–66]. A signiﬁcant
correlation has been demonstrated between VEGF-A and
VEGF-C expression and lymph node metastases [67, 68],
and patients overexpressing these two factors tend to show
decreased survival. On the contrary, VEGF-D has been
found to be underexpressed in HNC cells, and it is thought
that it has an antagonistic eﬀect on other VEGFs and
may play a role in the late process of neoangiogenesis
stabilisation.
Kishimotoetal.[69]investigatedtheassociationbetween
VEGF-C expression and regional lymph node metastases
in oral squamous cell carcinoma (OSCC) by examining
its immunohistochemical expression in biopsy specimens
obtained from 62 patients. In the early stages (T1 and
T2), VEGF-C expression closely correlated with lymph node
metastases (P<. 001), but there was no signiﬁcant corre-
lation in the advanced stages (T3 and T4). These ﬁndings
indicate that VEGF-C expression in biopsy specimens could
be used as a reliable predictor of regional lymph node
metastases, particularly in early OSCC, and may become
an important factor when choosing the most appropriate
treatment.
The limited data concerning tongue cancer are con-
ﬂicting. Kim et al. studied the expression of VEGF and
metalloproteinase-2 and -9 in 38 oral tongue cancer patients,
and found a signiﬁcant correlation between VEGF expres-
sion and the extent of tumour invasion (P = .002).
Furthermore, the tumour-free survival of the VEGF-positive
patients was signiﬁcantly worse than that of the VEGF-
negative patients (P = .019) [70]. However, Faustino
et al. did not ﬁnd a a similar correlation in early stage
OSCC: 60 out of 87 patients (68.9%) were aﬀected by
tongue cancer and it was found that VEGF-C expression
did not predict occult lymph node metastases in T1-T2N0
tumours [71]. In another study, Cho et al. found high VEGF
expression in 20 out of 33 specimens of resected tongue
cancer(60.6%),butnocorrelationbetweenitandrecurrence
(P = .33) [72]; the expressions of maspin, an inhibitor of
angiogenesis and tumour suppressant [73, 74], and mutant-
type p53 were also evaluated but did not correlate with
recurrent disease. We studied 56 patients undergoing radical
surgery for tongue cancer and found that the expression
of VEGF-C and its receptor VEGFR-2 correlated with DFS
but not OS (unpublished data). Although there is some
evidencethatVEGF-Cplaysaroleincausingmoreaggressive
tongue cancer, further studies of larger patient series are
needed.
5. Tight JunctionalProteins
There are three main types of intercellular junctions: tight,
adherens, and gap junctions. The most apical components
of the junctional complexes are tight junctions (TJs),
which play a major role as paracellular barriers to the
transport of ions, water, and proteins, and are also believed
to be involved in the signalling cascades controlling cell
growth and diﬀerentiation. Together with desmosomes,
they form part of cell-to-cell adhesion apparatuses, and
strongly regulate the invasion of cancer cells [75–81]. TJs
are involved in the neoplastic process because they couple
the extracellular milieu to intracellular signalling pathways
and the cytoskeleton [82]. Deranged TJ permeability may
increase the diﬀusion of nutrients and other factors that
promote tumour growth and/or survival [83].
Claudins and occludin are tight junctional proteins
whose expression has been studied in various tumour types
[84], and tentatively correlated with tumour proliferation
as a result of a mechanism involving the activity of
matrix metalloproteinases [85]. Claudin 7 is known to be
underexpressed in HNC [24], but only Bello et al. have
described its expression in tongue cancer. They analysed
the distribution of claudins (1, 4, 5, and 7) and occludin
in 97 patients with superﬁcial and invasive front of tongue
cancer, and found that claudins 1 and 7 were strongly
expressed, claudin 4 moderately expressed, and claudin 5
the least expressed; occludin staining was irrelevant. Cause-
speciﬁc survival analysis showed that, in comparison with
intermediate immunoreactivity, high and low claudin 7
immunoreactivity tended to be associated with decreased
survival [86]. The authors suggested that claudin 7 levels
could be used for prognostic purposes, but the subjective
nature of the immunohistochemical evaluation requires
caution.
6.ErbB2-Ki-67: Tyrosine-Kinase(b)
ErbB2 (HER-2/neu) is a tyrosine kinase transmembrane
receptor that belongs to the family of epidermal growth
factor receptors (EGFRs), like ErbB1/HER-1, ErbB3/HER-
3, and ErbB4/HER-4. It can be activated by means of
heterodimerisation with the other members of the family,
andisin v olv edincellpr oliferationanddiﬀerentiation.Italso
plays a major role in tumour invasion via mitogen-activated
protein kinase (MAPK) or phosphatidylinositol 3-kinase-
(PI3K) AKT-activated pathways [87, 88]. Many (but not all)
authors have demonstrated ErbB2 overexpression and gene
ampliﬁcation in oral SCC, and that they are associated with
early recurrence, local, and distant metastases, or shorter
survival [89–94]. Fatty acid synthase (FAS) is located in the
cytosol and is responsible for the endogenous synthesis of
saturated long-chain fatty acids. Its expression is upregulated
in a number of human epithelial malignancies, including
OSCC [95–100]. It has been shown that the overexpression
of human ErbB2 in mouse ﬁbroblasts stimulates FAS protein
expression through a PI3K-dependent pathway. FAS is
essential for cell proliferation, and its speciﬁc inhibition4 Journal of Oncology
reduces cell growth, blocks DNA replication, and promotes
apoptosis in various cancer cell lines [101, 102].
Silva et al. have shown that intracytoplasmatic ErbB2
expression correlates with the 10-year survival of tongue
cancer patients, which was 24.1% in the case of high
expression, and 53.4% in the case of weak or negative
expression (log-rank test, P = .0096). The proliferation
index, evaluated by means of Ki-67, signiﬁcantly predicted
both OS (log-rank test, P = .0001) and DFS (log-rank
test, P = .0047); however, it did not correlate with the cell
surface coexpression of FAS and ErbB2, thus indicating a
favourableprognosisinbothcases[103].Thesamegrouphas
also studied the microscopic characteristics of tongue cancer,
and found that histological grade (P<. 05), lymphatic
permeation (P<. 001), perineural inﬁltration (P<. 05),
and nodal metastases (P<. 02) are all associated with
FAS status. High FAS expression correlates with aggressive
histological features and may be important for tumour
progression [104]. Diﬀerent results have been obtained in
tongue cancer using the Hercept test, which demonstrated
that the expression of Erb B2 does not correlate with
clinicopathological parameters and is not useful in treatment
decision making [105].
7. p-53
The p53 tumour suppressor gene is located on the short arm
ofhumanchromosome17andencodesforaphosphoprotein
that has dual activity on normal cells: it inhibits cell
proliferation by arresting it at the G1-phase after DNA
damage, and it induces apoptosis after genotoxic damage.
It is thought that both mechanisms also suppress tumour
growth [106].
The expression of p53 is strikingly important in the
response to irradiation or cytotoxic drugs, and it has been
shownthatanalterationinthep53genemaycausetreatment
failure in cancer patients as it prevents the triggering of the
apoptotic pathway [107, 108]. Many environmental factors
can alter p53 function, as has been demonstrated in the case
of cigarette smoking and asbestos exposure in lung cancer
[109, 110]. Exogenous factors can easily and directly act on
cells in the oral cavity, but the role of cigarette smoking in
deregulating p53 protein is still unclear [111, 112].
Atula et al. [113] have studied p53 mutations and protein
expression in tongue cancer, and found mutations in 54% of
the samples by means of single-stranded conformation poly-
morphism (SSCP) analysis, which correlated with tumour
size (41% in T1-2 versus 90% in T3-4; Fisher’s exact test,
P<. 01) and grading (75% of grade 2-3 versus 32% of
low-grade cancers; chi-squared test, P<. 01). Although
experimental models have demonstrated that p53 mutations
precede and favour the appearance of metastases [114, 115],
this study found no correlation between metastases and
p53 mutations or protein expression, a ﬁnding that can be
explained on the grounds of the progressive accumulation
of mutations during the course of cancer or viewed as
an early event contributing to more aggressive behaviour.
Tongue cancer develops as a sum of several environmental
and genetic factors aﬀecting the same cell, thus leading
to its progressive malignant transformation and metastatic
dissemination [116].
The expression of p53 in oral leukoplakia is higher
than in cancer of the tongue and should probably be
considered an early event in tumour progression [117].
Nagler et al. studied 116 patients with tongue cancer, and
found the 5-year probability of OS was 55%, and better for
mobile tongue than base of the tongue cancer (70% versus
32%, P = .0008). Immunohistological analysis of p53, the
antiapoptotic protein Bcl-2 and c-erbB-2, and an assessment
oftherateofapoptosisbymeansofterminaldUTPnick-end-
labelling (TUNEL), in 55 specimens, revealed a signiﬁcant
correlation between p53 and TUNEL staining, but the link
with prognosis needs to be studied further [118]. It has
also been found that p53 positivity is not a reliable means
of selecting patients for elective neck dissection in the
management of N0 oral tongue cancer [119].
8. Osteopontin
Osteopontin (OPN) is a calcium binding protein that binds
alpha rather than beta integrin and CD44 receptors, and
activates intracellular signalling pathways associated with
cell adhesion and migration [120–122]. It is expressed and
secreted by many kinds of cancers, and has been associated
with tumour progression and invasion [123–126]. It can also
be induced by VEGF and is involved in vessel angiogenesis
and endothelial cell survival [127–129]. Matsuzaki et al.
[130] failed to demonstrate a correlation between OPN
expression and lymphatic metastases and survival in T1-4
tongue cancer, but OPN expression has also been studied in
T1-2tonguecancerusingadiﬀerentmeansofimmunohisto-
chemical evaluation [131]. Thirty out of 94 patients (31.9%)
expressed OPN and this signiﬁcantly correlated with a more
advanced T stage (T2 versus T1) (P = .004), positive lymph
nodes (P<. 001), the presence of tumor necrosis (P = .016),
and greater tumour thickness (P<. 001). Interestingly, the
patients expressing OPN showed a signiﬁcantly lower DFS
rate (63.4% versus 92.8%; log-rank test, P<. 001).
Using the method developed by Matsuzaki et al. [130],
OPN expression still signiﬁcantly related to the expression
of VEGF and CD105 (both P<. 001), tumour invasion
depth (P = .001), and regional nodal metastases (P<. 001),
and Chien et al. [131] conﬁrmed the relationship between
OPN and VEGF, thus suggesting their importance in the
development of new vessels in early tongue cancer. Hypoxia
can also contribute to the increased expression of OPN
and the activation of other important angiogenetic factors.
These data argue in favour of a role of OPN in predicting
a poor prognosis, and, therefore, possibly in inﬂuencing the
decision to adopt more aggressive therapy.
9. Survivin:OSCC (c)
A large number of cancer cells acquire resistance to treat-
ment by evading apoptosis, and a family of inhibitors of
apoptosis proteins (IAPs) can interfere with programmedJournal of Oncology 5
cell death [132, 133] .T h eu l t i m a t ee ﬀectors of the apop-
totic machinery are the intracellular proteases called cas-
pases [134]. Caspase-8 and -9 trigger the activation of
more caspases that execute the cell death program. It
is believed that survivin, which is encoded by the gene
BIRC5, blocks caspase-mediated death by forming a stable
complex with X-IAP, which has a synergistic inhibitory
action on apoptosis [135]. Survivin is highly expressed
in many cancer types and has been associated with a
more aggressive phenotype and poor outcome in oral SCC
[136]. In their study of OSCC in Taiwan, Lin et al. found
no signiﬁcant correlation between survivin expression and
patient age, gender, oral habits, cancer location, or TNM
status, but the patients with high survivin expression, an
advanced stage, a larger tumour size or positive lymph
node metastases had a signiﬁcantly shorter OS than the
others (P = .014, .012, .005, and .011, log-rank test)
[137]. Survivin protein expression may thus be considered
an important early event in oral carcinogenesis and predicts
an unfavourable prognosis for OSCC. On the other hand,
Freier et al. found no statistical diﬀerence between tumours
with a gain in BIRC5 gene copy number and those with
a balanced BIRC5 locus (P>. 05) in terms of the
prevalence of high survivin expression, and high survivin
expression predicted longer OS in a subgroup of patients
with advanced tumours treated by radiotherapy [138].
The authors concluded that the additional BIRC5 copies
were probably biologically inactive, that another distinct
molecularmechanismmightberesponsibleforhighsurvivin
expression in OSCC, and that survivin might be used to
deﬁne better the patients who may beneﬁt from radiation
therapy.
The diﬀerence in these results may also have been due to
the evaluation system used, because the latter study used a
score that took into account both nuclear and cytoplasmic
cells. A study of nuclear staining alone in breast and colon
cancer found a correlation with better survival, and so it is
reasonable to imagine that Freier’s ﬁnding of an impact on
survival was due to the nuclear expression of survivin.
Unfortunately all of these studies involved OSCC series
that included only a minority of patients aﬀected by tongue
cancer. In our own recent series of tongue cancer patients,
immunohistochemical analysis of survivin did not correlate
with DFS or OS (unpublished data).
10.EGFR
Epidermal growth factor receptor (EGFR) is a 170-kDa
transmembrane glycoprotein whose gene is located on
chromosome 7p12. It is a member of the family of tyrosine
kinase (TK) growth factor receptors, a group of proteins
whose aberrant activity plays a key role in cell growth and
neoplastic progression [139, 140]. A number of extracellular
growth factor ligands, including epidermal growth factor
(EGF) and transforming growth factor alpha (TGF-α), bind
to EGFR and thus lead to the downstream activation of ras,
which ultimately leads to cell cycle progression, decreased
apoptosis, as well as increased angiogenesis and metastatic
properties [141, 142]. EGFR and its ligand TGF-α are over-
expressed in nearly all HNC [143, 144], and its expression is
typically associated with greater radio- chemoresistance and
shorter DFS and OS [145, 146]. EGFR expression has been
reported to be 29% and 50% in hypopharyngeal and oral
cavity cancers [147], and ranging from 42% to 80% in other
types of HNC [148, 149].
Few data are available concerning the expression and
prognostic value of EGFR in tongue cancer. EGFR mutations
arenotfrequent(theyhavebeenfoundin14%ofinvestigated
cases) and, unlike in nonsmall cell lung cancer (NSCLC),
they do not correlate with prognosis [150]. Treatment with
tyrosine kinase inhibitors is less eﬀective in HNC than
NSCLC [151, 152] although the types of mutations are very
similar [153]. Mahmoud et al. studied HNC specimens for
EGFR mutations and expression in a Japanese population
and found a silent mutation in only one case, thus reﬂecting
the low incidence reported in previous studies, whereas
overexpression (+2, +3) was found in 68% of the tumours.
EGFR overexpression was signiﬁcantly associated with poor
tumor diﬀerentiation (P = .02) and a positive nodal stage
(P = .032) [154].
As in the case of Western patients, mutations are rare
in Japanese HNC [155, 156], and protein overexpression
rather than mutation might be responsible for activating
the EGFR pathway. Ulanovski et al. studied 27 patients
who underwent surgery for SCC of the tongue. EGFR and
erb-B2 were expressed in 34% and 17% of the specimens,
but the authors could not demonstrate any association
between EGFR expression or erbB2, and tumour depth,
lymph node status, extracapsular invasion, recurrence, or
survival [157].
11. Conclusions
Cancer of the tongue is frequent and has a poor prognosis,
with a 5-year survival rate of less than 50%. Treatments
should be individualized on the basis of the biological
characteristics of the tumour with the aim of improving
locoregional control, preventing distant metastases, and
lengthening survival. The role of EBV and HPV is very
slight, although the latter may indicate a better prognosis.
Among hypoxia markers, only the expression of EPOR and
pimonidazole correlates with locoregional control and DFS,
but these ﬁndings are based on a small number of patients.
VEGF, tight junction proteins, and p53 expression hardly
correlate with poor prognostic features, and the survivin
ﬁndings are also controversial although it may be useful to
select a subpopulation of patients who may beneﬁt from
radiation therapy. The intracytoplasmic expression of erbB2
and the ki-67 proliferation index are associated with OS, and
FAS expression is related to aggressive histological features.
OPN is a VEGF-inducible factor, that is, overexpressed in
cases of aggressive cell behaviour, and is associated with
decreasedDFS,atleastinT1-2tumours.EGFRmutationsare
seldom found in tongue cancer and do not play a signiﬁcant
prognostic role; likewise, EGFR overexpression correlates
with nodal stage but not DFS or OS.6 Journal of Oncology
In this era of targeted therapies tailored on the biological
characteristicsof tumours, theresults, asfar astongue cancer
is concerned, are still poor and conﬂicting, and new insights
areeagerlyexpectedwiththeaimofoﬀeringthebestpossible
treatment to each patient.
Antiangiogenetics,anti-EGFR,tyrosine-kinaseinhibitors
andproapoptoticsareallfactorsdeservingfurtherevaluation
in order to improve outcomes in patients aﬀected by cancer
of the tongue.
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